![[(1R,3R,4S,7S,8S)-4-hydroxy-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,4,7,8-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate](https://veeprho.com/wp-content/uploads/2025/12/1R3R4S7S8S-4-hydroxy-8-2-2R4R-4-hydroxy-6-oxooxan-2-ylethyl-37-dimethyl-123478-hexahydronaphthalen-1-yl-22-dimethylbutanoate-NA-VE0026578-sqr.png "[(1R,3R,4S,7S,8S)-4-hydroxy-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,4,7,8-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate")
100% accuracy
of data
of data
24/7 scientific
support
support
0% tolerance in
quality of product
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
[(1R,3R,4S,7S,8S)-4-hydroxy-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,4,7,8-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
● In Stock
| Catalogue No.: | VE0026578 |
|---|---|
| CAS No.: | N/A |
| Mol. Formula: | C25H38O6 |
| Mol. Weight: | 434.57 g/mol |
Additional information on
Parent drug
SimvastatinIUPAC Name
[(1R,3R,4S,7S,8S)-4-hydroxy-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,4,7,8-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoateSmiles
O=C(O[C@@H]1C[C@@H](C)[C@H](O)C2=C1[C@@H](CC[C@@H]3C[C@@H](O)CC(O3)=O)[C@@H](C)C=C2)C(C)(CC)CInChI
InChI=1S/C25H38O6/c1-6-25(4,5)24(29)31-20-11-15(3)23(28)19-9-7-14(2)18(22(19)20)10-8-17-12-16(26)13-21(27)30-17/h7,9,14-18,20,23,26,28H,6,8,10-13H2,1-5H3/t14-,15+,16+,17+,18-,20+,23-/m0/s1Description
(1R,3R,4S,7S,8S)-4-hydroxy-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,4,7,8-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate, an identified process-related impurity, displays a complex stereochemical motif with multiple hydroxyl and ketone functionalities that increase polarity and influence chromatographic retention. Analytical profiling by HPLC, LC-MS and 1H/13C NMR supports definitive structure confirmation and quantification, while chiral HPLC resolves stereoisomeric content. Typically generated from incomplete esterification or oxidative ring transformations during synthesis, this impurity can impact assay, purity and stability. Effective control strategies include optimized reaction conditions, targeted purification and validated in-process monitoring to ensure levels remain within defined specifications and to inform stability and formulation risk assessments.Request a Quote
« * » indique les champs nécessaires
Other products related to Simvastatin impurities impurities
Impurity structure
Parent Drug Name
CAS No.
Name of Impurity
Catalog No.
![[(1R,3R,4S,7S,8S)-4-hydroxy-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,4,7,8-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate](https://veeprho.com/wp-content/uploads/2025/12/3-Hydroxy-Simvastatin-134523-09-4-VE0026498.png "[(1R,3R,4S,7S,8S)-4-hydroxy-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,4,7,8-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate")
![[(1R,3R,4S,7S,8S)-4-hydroxy-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,4,7,8-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate](https://veeprho.com/wp-content/uploads/2025/12/6-Carboxy-Simvastatin-114883-30-6-VE0026456.png "[(1R,3R,4S,7S,8S)-4-hydroxy-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,4,7,8-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate")
![[(1R,3R,4S,7S,8S)-4-hydroxy-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,4,7,8-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate](https://veeprho.com/wp-content/uploads/2025/12/23-Dehydro-Simvastatin-Acid-Sodium-Salt-393825-04-2-VE0026455.png "[(1R,3R,4S,7S,8S)-4-hydroxy-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,4,7,8-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate")
